I'm thinking it's 75-25 for reaching primary endpo
Post# of 148294
Remdesivir was able to show a semblance of effectiveness only by virtue of the federal government throwing a bunch of money into running a huge study and then changing the rules in the middle of the game (changing the metric for the primary endpoint near the end of the study).
Tocilizumab has been showing some positive results, but it is a little behind leronlimab in testing, is more limited in its MOA, and has more worrisome side effects.